BACKGROUND: Dengue virus (DENV) causes hundreds of millions of infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood of severe disease with a second, heterotypic DENV infection. METHODS: In a randomized, placebo-controlled study, the safety and immunogenicity of 4 different admixtures of a live attenuated tetravalent (LATV) dengue vaccine were evaluated in 113 flavivirus-naive adults. Serum neutralizing antibody levels to all 4 dengue viruses were measured on days 0, 28, 42, and 180. RESULTS: A single dose of each LATV admixture induced a trivalent or better neutralizing antibody response in 75%-90% of vaccinees. There was no significant difference in the incidence of adverse events between vaccinees and placebo-recipients other than rash. A trivalent or better response correlated with rash and with non-black race (P < .0001). Black race was significantly associated with a reduced incidence of vaccine viremia. CONCLUSIONS: TV003 induced a trivalent or greater antibody response in 90% of flavivirus-naive vaccinees and is a promising candidate for the prevention of dengue. Race was identified as a factor influencing the infectivity of the LATV viruses, reflecting observations of the effect of race on disease severity in natural dengue infection.
RCT Entities:
BACKGROUND:Dengue virus (DENV) causes hundreds of millions of infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood of severe disease with a second, heterotypic DENVinfection. METHODS: In a randomized, placebo-controlled study, the safety and immunogenicity of 4 different admixtures of a live attenuated tetravalent (LATV) dengue vaccine were evaluated in 113 flavivirus-naive adults. Serum neutralizing antibody levels to all 4 dengue viruses were measured on days 0, 28, 42, and 180. RESULTS: A single dose of each LATV admixture induced a trivalent or better neutralizing antibody response in 75%-90% of vaccinees. There was no significant difference in the incidence of adverse events between vaccinees and placebo-recipients other than rash. A trivalent or better response correlated with rash and with non-black race (P < .0001). Black race was significantly associated with a reduced incidence of vaccine viremia. CONCLUSIONS: TV003 induced a trivalent or greater antibody response in 90% of flavivirus-naive vaccinees and is a promising candidate for the prevention of dengue. Race was identified as a factor influencing the infectivity of the LATV viruses, reflecting observations of the effect of race on disease severity in natural dengue infection.
Authors: Anna P Durbin; Stephen S Whitehead; Julie McArthur; John R Perreault; Joseph E Blaney; Bhavin Thumar; Brian R Murphy; Ruth A Karron Journal: J Infect Dis Date: 2005-01-27 Impact factor: 5.226
Authors: Ronald E Blanton; Luciano K Silva; Vanessa G Morato; Antonio R Parrado; Juarez P Dias; Paulo R S Melo; Eliana A G Reis; Katrina A B Goddard; Márcio R T Nunes; Sueli G Rodrigues; Pedro F C Vasconcelos; Jesuina M Castro; Mitermayer G Reis; Maurício L Barreto; M Glória Teixeira Journal: Eur J Hum Genet Date: 2008-02-13 Impact factor: 4.246
Authors: Wellington Sun; Dennis Cunningham; Steven S Wasserman; Judith Perry; J Robert Putnak; Kenneth H Eckels; David W Vaughn; Stephen J Thomas; Niranjan Kanesa-Thasan; Bruce L Innis; Robert Edelman Journal: Hum Vaccin Date: 2009-01-27
Authors: S B Halstead; T G Streit; J G Lafontant; R Putvatana; K Russell; W Sun; N Kanesa-Thasan; C G Hayes; D M Watts Journal: Am J Trop Med Hyg Date: 2001-09 Impact factor: 2.345
Authors: Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead Journal: Vaccine Date: 2011-07-21 Impact factor: 3.641
Authors: Annette Fox; Nguyen Minh Hoa Le; Cameron P Simmons; Marcel Wolbers; Heiman F L Wertheim; Thi Khuong Pham; Thi Hai Ninh Tran; Thi Minh Lien Trinh; Thi Lien Nguyen; Vu Trung Nguyen; Duc Hien Nguyen; Jeremy Farrar; Peter Horby; Walter R Taylor; Van Kinh Nguyen Journal: PLoS Negl Trop Dis Date: 2011-03-01
Authors: Alba Grifoni; Michael Angelo; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Jason Botten; Jonathan Boyson; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf Journal: J Virol Date: 2017-03-29 Impact factor: 5.103
Authors: Michael A Angelo; Alba Grifoni; Patrick H O'Rourke; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf Journal: J Virol Date: 2017-02-14 Impact factor: 5.103
Authors: Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Kari Opert; Adrienne P Jarvis; Beulah P Sabundayo; Benjamin D McElvany; Eli A Sendra; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Stephen S Whitehead Journal: J Infect Dis Date: 2016-02-16 Impact factor: 5.226
Authors: Scott A Smith; Ruklanthi de Alwis; Nurgun Kose; Anna P Durbin; Stephen S Whitehead; Aravinda M de Silva; James E Crowe Journal: J Infect Dis Date: 2013-03-22 Impact factor: 5.226